---
title: "Innovative Medical released its performance for the first three quarters, with a net profit attributable to the parent company of 4.7244 million yuan, a year-on-year increase of 116.97%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/262582062.md"
description: "According to the Zhitong Finance APP, Innovative Medical released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 597 million yuan, a year-on-year decrease of 2.11%. The net profit attributable to shareholders of the listed company was 4.7244 million yuan, a year-on-year increase of 116.97%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 29.4698 million yuan"
datetime: "2025-10-24T09:13:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/262582062.md)
  - [en](https://longbridge.com/en/news/262582062.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/262582062.md)
---

# Innovative Medical released its performance for the first three quarters, with a net profit attributable to the parent company of 4.7244 million yuan, a year-on-year increase of 116.97%

According to the Zhitong Finance APP, Innovative Medical (002173.SZ) released its third-quarter report for 2025. In the first three quarters, the company achieved an operating income of 597 million yuan, a year-on-year decrease of 2.11%. The net profit attributable to shareholders of the listed company was 4.7244 million yuan, a year-on-year increase of 116.97%. The net loss attributable to shareholders of the listed company, after deducting non-recurring gains and losses, was 29.4698 million yuan

### Related Stocks

- [002173.CN](https://longbridge.com/en/quote/002173.CN.md)

## Related News & Research

- [11:06 ETEndurance Named to Inc. 5000 for 11th Time, Continuing National Growth](https://longbridge.com/en/news/296124358.md)
- [Transportation and Logistics Systems delays Q2 10-Q filing after reverse stock split timing changes](https://longbridge.com/en/news/295962562.md)
- [Dicot Pharma submits EU clinical trial application for LIB-01 phase 2b study](https://longbridge.com/en/news/296068059.md)
- [07:55 ETSAPPHIRE LENSES & WINDOWS PROTECT SENSITIVE ELECTRO-OPTICAL SYSTEMS](https://longbridge.com/en/news/296224371.md)
- [PharmaCorp Rx closes Western Canada pharmacy acquisition for $2.47 million](https://longbridge.com/en/news/296225360.md)